HIND Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About HIND Interactive Breakdown Better Bets vs. HIND Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Vyome (HIND)

    Market Price (10/10/2026): $2.09 | Market Cap: $14.7 MilSector: Health Care | Industry: Biotechnology

    Vyome (HIND)

    Market Price (10/10/2026): $2.09
    Market Cap: $14.7 Mil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -54%

    Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -121%, 3Y Excs Rtn is -168%

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -4.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3250%

    Expensive valuation multiples
    P/SPrice/Sales ratio is 113x

    Weak revenue growth
    Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -67%, Rev Chg QQuarterly Revenue Change % is -46%

    Significant share based compensation
    SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 5106%

    Not cash flow generative
    CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4300%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -4300%

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -81%

    Key risks
    HIND key risks include [1] the failure of its lead drug candidate, Show more.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -54%
    1 Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.
    2 Weak multi-year price returns
    2Y Excs Rtn is -121%, 3Y Excs Rtn is -168%
    3 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -4.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3250%
    4 Expensive valuation multiples
    P/SPrice/Sales ratio is 113x
    5 Weak revenue growth
    Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -67%, Rev Chg QQuarterly Revenue Change % is -46%
    6 Significant share based compensation
    SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 5106%
    7 Not cash flow generative
    CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4300%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -4300%
    8 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -81%
    9 Key risks
    HIND key risks include [1] the failure of its lead drug candidate, Show more.

    Valuation & Metrics

    FYE: 12/31HIND [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.1 Mil—
    FY 2026 Sales$0.1 Mil—
    FY 2027 Sales$0.2 Mil—
    FY 2026 Sales Growth-46.3%—
    FY 2027 Sales Growth258.8%13.1%
    EARNINGS
    LTM Net Income (GAAP) [3]$-11.3 Mil—
    FY 2026 Net Income (Non-GAAP)$-1.4 Mil—
    FY 2027 Net Income (Non-GAAP)$-1.8 Mil—
    FY 2027 Net Income Growth—18.9%
    FY 2026 EPS (Non-GAAP)$-0.65—
    FY 2027 EPS (Non-GAAP)$-0.84—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S210.61.7
    FY 2027 P/S58.7—
    FY 2026 P/E—7.9
    FY 2027 P/E——

    [1] HIND forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 10/31/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    HINDS&P 500
    REVENUE GROWTHVERY POOR
    Rev LTM ($ Bil)0.0
    Rev Chg Q-46.0%9.3%
    Rev Chg LTM-67.1%8.3%
    Rev Chg 3Y Avg-67.1%5.9%
    PROFITABILITYVERY POOR
    Op Inc LTM ($ Bil)-0.0
    CFO LTM ($ Bil)-0.0
    Net Inc LTM ($ Bil)-0.0
    Op Mgn LTM-3,250.3%18.5%
    CFO/Rev LTM-4,300.5%21.9%
    Net Inc Mgn-8,716.8%13.3%
    VALUATIONVERY HIGH
    P/S113.13.1
    P/CFO-2.614.7
    P/FCF-2.619.0
    P/E-1.322.0
    STABILITYVERY GOOD
    Debt/Equity0.000.21
    Cash/Assets0.860.07

    AI Analysis | Feedback

    MetricValueDateSource
    Number of Patentsover 758152025Link
    Lead Drug CandidateVT-1953 in Phase 2 study for Malignant Fungating Wounds942025Link
    Drug Pipeline: Uveitis TreatmentVT-1908 in preclinical development10292025Link
    Drug Pipeline: Drug-Resistant Acne TreatmentVB-1953 has completed a Phase 2 study10292025Link
    Patient Enrollment in VB-1953 studiesmore than 55010292025Link

    Price Chart

    Upcoming
    11/13/2026Earnings ReleaseRev: $24111 (E)
    EPS: $-0.20 (E)

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 10/6/2026

    Vyome (HIND) stock has lost about 5% since 6/30/2026 because of the following key factors:

    1. Broader Biotech Sector Weakness and Market Selectivity. The U.S. biopharma market experienced a more selective environment during fiscal Q3 2026. While the XBI, a key biotech index, reached a five-year high in August, it subsequently sold off, closing fiscal Q3 at approximately $158. This trend saw clinical-stage and small-to-mid-cap companies, such as Vyome (HIND), underperform larger-cap and commercial-stage peers.

    2. Challenging Funding Environment and Reduced Dealmaking. Dealmaking within the healthcare and life sciences sector significantly cooled during fiscal Q3 2026. R&D partnership value declined by 43.7% to $47.9 billion, M&A value fell by 49% to $57.1 billion, and venture funding decreased by 14% to $12.4 billion. This broader reduction in capital flow and deal activity likely contributed to investor caution regarding clinical-stage biopharmaceutical companies like Vyome, which often rely on external funding for development.

    Show more
    Updated on 10/6/2026

    Vyome (HIND) stock has lost about 5% since 6/30/2026 because of the following key factors:

    1. Broader Biotech Sector Weakness and Market Selectivity. The U.S. biopharma market experienced a more selective environment during fiscal Q3 2026. While the XBI, a key biotech index, reached a five-year high in August, it subsequently sold off, closing fiscal Q3 at approximately $158. This trend saw clinical-stage and small-to-mid-cap companies, such as Vyome (HIND), underperform larger-cap and commercial-stage peers.

    2. Challenging Funding Environment and Reduced Dealmaking. Dealmaking within the healthcare and life sciences sector significantly cooled during fiscal Q3 2026. R&D partnership value declined by 43.7% to $47.9 billion, M&A value fell by 49% to $57.1 billion, and venture funding decreased by 14% to $12.4 billion. This broader reduction in capital flow and deal activity likely contributed to investor caution regarding clinical-stage biopharmaceutical companies like Vyome, which often rely on external funding for development.

    3. Market Caution Due to Federal Reserve Rate Hike. The Federal Reserve implemented a 25-basis-point interest rate hike in September 2026, accompanied by expectations of further increases by year-end. This reinforced a more cautious market tone, generally impacting growth-oriented sectors like biotechnology, where future earnings potential is discounted more heavily in a rising interest rate environment.

    4. Mixed Analyst Sentiment and Bearish Technical Signals. Analyst sentiment for Vyome (HIND) was mixed during the period, with some analysts maintaining a "Strong Buy" rating and high price targets (e.g., an average of $8.83 from 3 analysts as of September 3, 2026), while others offered a "Hold" consensus with a lower average price target of $3.50 as of October 3, 2026. Additionally, technical indicators turned bearish in September 2026, with the 10-day moving average crossing below the 50-day moving average and the Moving Average Convergence Divergence Histogram (MACD) turning negative, signaling potential downward momentum. This divergence in fundamental outlook and technical weakness likely contributed to selling pressure.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -2.8% change in HIND stock from 6/30/2026 to 10/9/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).
    (LTM values as of)630202610092026Change
    Stock Price ($)2.152.09-2.8%
    Change Contribution By: 
    Total Revenues ($ Mil)�00.0%
    P/S Multiple�29.50.0%
    Shares Outstanding (Mil)660.0%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    6/30/2026 to 10/9/2026
    ReturnCorrelation
    HIND-2.8% 
    Market (SPY)4.3%8.8%
    Sector (XLV)7.7%15.7%

    Fundamental Drivers

    The -2.8% change in HIND stock from 3/31/2026 to 10/9/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).
    (LTM values as of)331202610092026Change
    Stock Price ($)2.152.09-2.8%
    Change Contribution By: 
    Total Revenues ($ Mil)�00.0%
    P/S Multiple�29.50.0%
    Shares Outstanding (Mil)660.0%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    3/31/2026 to 10/9/2026
    ReturnCorrelation
    HIND-2.8% 
    Market (SPY)20.0%14.3%
    Sector (XLV)17.0%16.3%

    Fundamental Drivers

    null
    null

    Market Drivers

    9/30/2025 to 10/9/2026
    ReturnCorrelation
    HIND-59.7% 
    Market (SPY)17.8%19.1%
    Sector (XLV)24.3%22.4%

    Fundamental Drivers

    null
    null

    Market Drivers

    9/30/2023 to 10/9/2026
    ReturnCorrelation
    HIND  
    Market (SPY)88.4%14.6%
    Sector (XLV)38.9%18.7%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    HIND Return-----75%-41%-86%
    Peers Return19%-13%-1%74%40%-6%133%
    S&P 500 Return27%-19%24%23%16%13%107%

    Monthly Win Rates [3]
    HIND Win Rate----20%40% 
    Peers Win Rate53%53%47%52%58%48% 
    S&P 500 Win Rate75%42%67%75%67%50% 

    Max Drawdowns [4]
    HIND Max Drawdown------47% 
    Peers Max Drawdown-45%-44%-61%-49%-48%-36% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: ARQT, ACRS, VRCA, INCY, REGN.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 10/9/2026 (YTD)

    How Low Can It Go

    HIND has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

    EventXLVS&P 500
    2025 US Tariff Shock
      % Loss-11.7%-18.8%
      % Gain to Breakeven13.3%23.1%
      Time to Breakeven142 days79 days
    2022 Inflation Shock & Fed Tightening
      % Loss-13.8%-24.5%
      % Gain to Breakeven15.9%32.4%
      Time to Breakeven166 days427 days
    2020 COVID-19 Crash
      % Loss-27.9%-33.7%
      % Gain to Breakeven38.8%50.9%
      Time to Breakeven77 days140 days
    Q4 2018 Fed Policy Error / Growth Scare
      % Loss-15.0%-19.2%
      % Gain to Breakeven17.6%23.8%
      Time to Breakeven191 days105 days
    2015-2016 China Devaluation / Global Growth Scare
      % Loss-15.9%-12.2%
      % Gain to Breakeven18.9%13.9%
      Time to Breakeven165 days62 days
    2011 US Debt Ceiling Crisis & European Contagion
      % Loss-15.8%-17.9%
      % Gain to Breakeven18.8%21.8%
      Time to Breakeven153 days123 days

    Compare to ARQT, ACRS, VRCA, INCY, REGN

    In The Past

    State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    HIND has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

    EventXLVS&P 500
    2020 COVID-19 Crash
      % Loss-27.9%-33.7%
      % Gain to Breakeven38.8%50.9%
      Time to Breakeven77 days140 days
    2008-2009 Global Financial Crisis
      % Loss-37.9%-53.4%
      % Gain to Breakeven61.1%114.4%
      Time to Breakeven767 days1085 days

    Compare to ARQT, ACRS, VRCA, INCY, REGN

    In The Past

    State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Vyome (HIND)

    ReShape Lifesciences Inc. (HIND) is a medical device company dedicated to developing and providing products and services for the management and treatment of obesity and metabolic diseases. The company focuses on offering less invasive solutions compared to traditional surgical procedures, alongside comprehensive patient support programs, to improve health outcomes for individuals struggling with weight-related conditions.

    Its product portfolio features several key solutions, including the Lap-Band System, a minimally invasive, long-term treatment for severe obesity that offers an alternative to more invasive gastric surgeries. Additionally, ReShape Lifesciences is developing the ReShape Vest system, an investigational device designed to aid weight loss by wrapping around the stomach without permanent alteration or bypassing parts of the gastrointestinal tract. The company also provides the Obalon Balloon System, a swallowable capsule used for tracking balloon placement, and the ReShapeCare virtual health coaching program, which offers telehealth support for patients undertaking medically managed weight-loss journeys.

    ReShape Lifesciences Inc. primarily serves obese and morbidly obese patients, as well as those with metabolic diseases such as type 2 diabetes mellitus, for which it has a preclinical neuromodulation technology in development. The company has a global reach, operating in the United States, Australia, Europe, and other international markets, aiming to provide accessible and effective treatments to a broad patient population.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Key Risks to Vyome (HIND)

    The key risks to Vyome (symbol: HIND) are:

    1. Clinical Development and Regulatory Approval Risk: As a clinical-stage company, Vyome's future success is highly dependent on the successful completion of clinical trials, particularly the ongoing Phase 3 trials for its lead asset VT-1953, and obtaining regulatory approvals from authorities such as the FDA. Failure to achieve positive clinical trial results or secure timely regulatory clearance would significantly impede the company's ability to commercialize its drug candidates and generate revenue.
    2. Financial Risk and Need for Capital: Developing and commercializing new drug candidates and medical devices is a capital-intensive endeavor. Although Vyome has recently secured funding for its initial Phase 3 trial requirements, the company will likely need substantial additional financing to complete clinical development, advance its pipeline assets, and support commercialization. The predecessor company, ReShape Lifesciences, also faced challenges in maintaining compliance with Nasdaq's minimum stockholders' equity requirements, indicating ongoing financial stability as a critical consideration.
    3. Market Competition and Acceptance: Vyome operates in highly competitive healthcare sectors, including medical devices for obesity (a legacy from ReShape Lifesciences) and new drug development for immuno-inflammatory conditions and oncology supportive care. There is a risk that Vyome's products, both existing medical devices and new drug candidates, may not achieve sufficient market acceptance or may face intense competition from established or emerging therapies and devices offered by other companies.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Share Repurchases

    No significant share repurchases by Vyome Holdings (HIND) or its predecessor, ReShape Lifesciences Inc. (RSLS), have been reported over the last 3-5 years. ReShape Lifesciences Inc. reported "N/A" for share buybacks in fiscal year 2024.

    Share Issuance

    • Vyome Holdings (HIND) raised approximately $5.29 million by selling 1,089,045 shares at an average price of $5.00 through its At-The-Market (ATM) facility by January 2026 to fund its VT-1953 Phase 3 trial.
    • ReShape Lifesciences Inc. (RSLS), prior to its merger, implemented multiple reverse stock splits, including a 1-for-25 split in May 2025 and a 1-for-4 split effective with the merger on August 15, 2025, to maintain NASDAQ listing compliance.
    • In April 2025, ReShape Lifesciences Inc. received shareholder approval for an Equity Line of Credit (ELOC) Purchase Agreement from December 2024, allowing it to sell up to $5 million in shares over 36 months to an institutional investor.

    Inbound Investments

    • ReShape Lifesciences Inc. completed an all-stock merger with Vyome Therapeutics, forming Vyome Holdings, Inc. (HIND), which began trading on Nasdaq on August 15, 2025.
    • Vyome Holdings (HIND) utilized an At-The-Market (ATM) facility to raise approximately $5.29 million by January 2026 to fund the initial Phase 3 interim results for its lead drug candidate, VT-1953.

    Outbound Investments

    • ReShape Lifesciences Inc., as part of the merger agreement, sold substantially all of its assets, including the Lap-Band System, Obalon Gastric Balloon System, and Diabetes Bloc-Stim Neuromodulation System, to Biorad Medisys (or an affiliate), with Biorad assuming most of ReShape's liabilities.
    • Vyome Holdings (HIND) launched its AI strategy with the acquisition of MIT startup Oculo, Inc. to develop an AI business unit.
    • Vyome, through its 70%-owned subsidiary Livechain Inc., acquired senior, secured convertible debt of Humanyze via an all-stock purchase, valued at approximately $325,000, and is taking over Humanyze's business assets and operations.

    Capital Expenditures

    • ReShape Lifesciences Inc. reported "N/A" for capital expenditures in fiscal year 2024.
    • Vyome Holdings (HIND) is currently funding the estimated costs for its VT-1953 Phase 3 clinical trial, with interim results anticipated in mid-2027.
    • For the first quarter of 2025, ReShape Lifesciences Inc.'s research and development expenses decreased by $0.1 million, or 24.8%, to $0.4 million, compared to the same period in the prior year.

    Peer Outperformance in Biotechnology

    null
    Share of Biotechnology constituents that HIND has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    24%
    of 454 industry peers · -62.0% return
    3Y
    —
    insufficient peer history
    5Y
    —
    insufficient peer history
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is HIND's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 6 14.1%44.9%95.6% CAH 440% · MCK 381% · COR 186%
    Health Care Services 20 23.0%31.5%12.1% HIMS 319% · RDNT 151% · DGX 79%
    Managed Health Care 8 33.9%-6.4%5.7% OSCR 125% · HQY 43% · ELV 15%
    Health Care Facilities 24 0.9%6.8%4.0% THC 326% · NHC 282% · ENSG 139%
    Health Care Equipment 50 -5.2%-2.8%-16.6% POCI 11350% · UFPT 350% · GKOS 267%
    Pharmaceuticals 62 -10.3%-3.2%-29.9% INDV 1102% · ETON 1006% · LQDA 903%
    Health Care Supplies 12 25.5%-8.2%-36.1% LNTH 322% · HAE 76% · MMSI 20%
    Life Sciences Tools & Services 109 -11.5%-10.1%-63.5% SNWV 2194% · NTRA 251% · MEDP 224%
    Biotechnology ← 364 -20.8%-25.7%-80.0% CELZ 1098% · DNTH 1092% · TRVI 999%
    Health Care Technology 21 -34.8%-58.6%-82.2% SPOK 74% · HSTM 19% · VEEV 3%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    PCRXPacira BioSciences1.444.0%40.3%
    OPCHOption Care Health4.837.2%-2.5%
    PTCPTC22.335.0%11.6%
    PRMEPrime Medicine0.733.9%15.0%
    PCVXVaxcyte10.326.4%54.7%
    QDELQuidelOrtho0.924.6%-53.0%
    RXORXO4.924.4%130.1%
    PENGPenguin Solutions3.924.3%290.0%
    NVAXNovavax2.121.9%89.7%
    HPKHighPeak Energy1.221.7%101.5%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    AVBPArriVent BioPharma0.8-40.8%-16.8%
    ALMRAlamar Biosciences1.5-26.5%14.9%
    NUAINew Era Energy & Digital0.5-25.4%60.2%
    SHAZSharonAI0.7-25.3%-59.0%
    ANGOAngioDynamics0.5-23.8%-10.3%
    GLASGlass House Brands0.4-22.4%-51.9%
    EOSEEos Energy Enterprises0.9-21.5%-78.0%
    AEHRAehr Test Systems2.7-21.1%319.2%
    YSSYork Space Systems0.9-20.8%-78.8%
    AXTIAXT4.2-20.3%318.7%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    MYPSPLAYSTUDIOS0.5740.5%530.4%
    KODKodiak Sciences6.3203.8%257.2%
    DNAGinkgo Bioworks0.891.7%56.4%
    PACBPacific Biosciences of California0.783.5%24.6%
    GRALGRAIL6.181.3%64.2%
    IOVAIovance Biotherapeutics6.679.6%435.5%
    SECZSecuritize2.071.9%12.4%
    MRNAModerna89.564.7%663.0%
    PEverpure51.464.2%130.7%
    PENGPenguin Solutions3.956.9%290.0%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    CTVACorteva8.9-84.3%-80.1%
    LQDALiquidia2.4-59.6%-20.6%
    XNDUXanadu Quantum Technologies1.2-56.6%-66.1%
    QUREuniQure1.5-49.2%-5.6%
    EMATEvolution Metals & Technologies1.0-46.8%-92.3%
    GLASGlass House Brands0.4-46.6%-51.9%
    NKTRNektar Therapeutics1.4-41.7%-2.6%
    AVBPArriVent BioPharma0.8-41.7%-16.8%
    ALHCAlignment Healthcare1.6-40.9%-61.8%
    ABRArbor Realty Trust0.5-40.3%-59.2%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    HINDARQTACRSVRCAINCYREGNMedian
    NameVyome Arcutis .Aclaris .Verrica .Incyte Regenero. 
    Mkt Price2.0926.463.824.16112.80750.0015.31
    Mkt Cap0.03.50.50.122.677.12.0
    Rev LTM04648305,82015,535247
    Op Inc LTM-434-86-261,8404,17415
    FCF LTM-639-62-131,8903,57517
    FCF 3Y Avg--73-58-428993,439-42
    CFO LTM-639-62-131,9804,68117
    CFO 3Y Avg--68-46-429744,498-42

    Growth & Margins

    HINDARQTACRSVRCAINCYREGNMedian
    NameVyome Arcutis .Aclaris .Verrica .Incyte Regenero. 
    Rev Chg LTM-67.1%76.1%-51.0%106.2%26.9%9.3%18.1%
    Rev Chg 3Y Avg-402.8%-32.0%57.8%18.5%7.0%18.5%
    Rev Chg Q-46.0%59.3%-8.3%-53.8%37.7%16.7%4.2%
    QoQ Delta Rev Chg LTM-15.1%11.6%-1.8%-18.4%8.6%4.1%1.2%
    Op Inc Chg LTM-297.7%139.9%-46.3%31.6%85.0%6.1%18.9%
    Op Inc Chg 3Y Avg-78.4%1.1%-50.5%552.7%-1.7%1.1%
    Op Mgn LTM-3,250.3%7.4%-1,040.4%-87.2%31.6%26.9%-39.9%
    Op Mgn 3Y Avg--53.8%-548.3%-304.4%18.3%28.2%-53.8%
    QoQ Delta Op Mgn LTM-842.0%6.6%-102.4%-50.8%4.6%1.1%-24.8%
    CFO/Rev LTM-4,300.5%8.5%-755.1%-44.0%34.0%30.1%-17.8%
    CFO/Rev 3Y Avg--50.1%-338.6%-279.3%18.1%31.2%-50.1%
    FCF/Rev LTM-4,300.5%8.5%-756.5%-44.0%32.5%23.0%-17.8%
    FCF/Rev 3Y Avg--52.1%-412.7%-280.0%16.5%23.9%-52.1%

    Valuation

    HINDARQTACRSVRCAINCYREGNMedian
    NameVyome Arcutis .Aclaris .Verrica .Incyte Regenero. 
    Mkt Cap0.03.50.50.122.677.12.0
    P/S113.17.466.32.93.95.06.2
    P/Op Inc-3.5100.8-6.4-3.412.318.54.5
    P/EBIT-1.380.0-6.4-3.211.514.85.1
    P/E-1.3121.1-7.2-2.814.017.86.4
    P/CFO-2.687.9-8.8-6.611.416.54.4
    Total Yield-77.1%0.8%-13.9%-35.6%7.1%6.1%-6.5%
    Dividend Yield0.0%0.0%0.0%0.0%0.0%0.5%0.0%
    FCF Yield 3Y Avg--5.9%-35.9%-382.1%4.8%4.9%-5.9%
    D/E0.00.00.00.00.00.00.0
    Net D/E-0.5-0.0-0.2-0.1-0.2-0.1-0.1

    Returns

    HINDARQTACRSVRCAINCYREGNMedian
    NameVyome Arcutis .Aclaris .Verrica .Incyte Regenero. 
    1M Rtn1.5%11.0%-31.3%-17.8%-10.5%-7.1%-8.8%
    3M Rtn-7.1%-4.6%-31.5%-33.5%-3.4%13.0%-5.9%
    6M Rtn-4.6%9.3%-5.4%-18.6%17.4%0.4%-2.1%
    12M Rtn-62.0%27.8%95.9%-3.3%33.1%32.3%30.0%
    3Y Rtn-85.1%449.0%-36.7%-89.2%97.1%-9.3%-23.0%
    1M Excs Rtn-3.4%10.3%-33.5%-18.9%-11.4%-8.4%-9.9%
    3M Excs Rtn-10.6%-6.4%-34.5%-33.7%-5.2%9.3%-8.5%
    6M Excs Rtn-19.2%-5.2%-20.0%-33.4%2.8%-14.2%-16.7%
    12M Excs Rtn-80.1%9.0%85.4%-21.7%16.5%18.0%12.7%
    3Y Excs Rtn-168.3%405.2%-119.5%-173.4%10.7%-90.7%-105.1%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/2024
    Filing Date8/12/20265/12/20263/18/202611/14/20258/12/20265/12/20263/18/202611/14/2025
    Key Financials Quarterly        
    Total Revenue00000000
    Ebitda-1-1-1-9-0-0-0-0
    Operating Income-1-1-1-1-0-0-0-0
    Net Income-1-1-1-9-0-0-0-1
    EPS-0.10-0.15-0.18-3.12-0.06-0.05-0.06-0.10
    Key Financials TTM        
    Total Revenue TTM00000---
    Ebitda TTM-12-11-10-9-1---
    Operating Income TTM-4-4-3-2-1---
    Net Income TTM-11-11-10-10-1---
    Growth Rates Quarterly        
    Total Revenue Growth-46.0%-84.1%-40.5%-59.0%----
    EBITDA Growth-185.9%-323.4%-407.0%-1621.6%----
    Operating Income Growth-166.1%-467.8%-429.3%-209.2%----
    Net Income Growth-122.0%-227.5%-247.1%-1469.1%----
    Margins Quarterly        
    EBITDA Margin-2647.9%-3102.4%-3466.5%-24740.5%-499.8%-116.6%-406.8%-588.7%
    Operating Income Margin-3200.0%-3576.8%-3707.4%-2509.0%-649.0%-100.2%-416.8%-332.4%
    Net Income Margin-2543.3%-3048.1%-2910.9%-24822.5%-618.1%-148.0%-499.1%-648.1%
    Cash & Debt        
    Total Cash8956--0-
    Total Debt00000040
    Net Debt / (Cash)-8-9-5-6--4-
    Cash Flows Quarterly        
    FCF from Operations-1-1-1-2-0-0-0-0
    Cash Flows TTM        
    FCF from Operations TTM-6-5-4-2-1---
    Returns to Shareholders Quarterly        
    Dividends00000000
    Share Repurchases-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly        
    ROIC-3.9%-5.2%-6.4%-4.2%---1.9%-
    Return on Invested Capital (ROIC) TTM        
    ROIC TTM-4.8%-4.3%-3.2%-2.0%----

    Segment Financials

    Revenue by Segment
    $ Mil202520232022
    Pharmaceutical000
    Biotechnology000
    Total000


    Net Income by Segment
    $ Mil202520232022
    Pharmaceutical000
    Biotechnology-11-1-1
    Total-10-1-1


    Assets by Segment
    $ Mil2025
    Biotechnology6
    Pharmaceutical0
    Total6


    Price Behavior

    Price Behavior
    Market Price$2.09 
    Market Cap ($ Bil)0.0 
    First Trading Date10/06/2016 
    Distance from 52W High-66.9% 
       50 Days200 Days
    DMA Price$3.46$6.74
    DMA Trenddowndown
    Distance from DMA-39.7%-69.0%
     3M1YR
    Volatility42.5%76.7%
    Downside Capture45.64220.48
    Upside Capture-0.7269.85
    Correlation (SPY)6.7%20.6%
    HIND Betas & Captures as of 9/30/2026

     1M2M3M6M1Y3Y
    Beta-0.89-0.280.180.501.140.93
    Up Beta-5.24-0.420.450.571.21-0.05
    Down Beta2.382.301.311.031.05-1.00
    Up Capture-137%-70%-34%11%37%-0%
    Bmk +ve Days6162766132424
    Stock +ve Days9182750101111
    Down Capture82%-1%24%61%149%96%
    Bmk -ve Days16263760120328
    Stock -ve Days12223468139159

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with HIND
    HIND-64.5%76.8%-1.02-
    Sector ETF (XLV)19.8%15.8%0.9421.7%
    Equity (SPY)16.7%13.0%0.9120.9%
    Gold (GLD)3.3%29.5%0.116.0%
    Commodities (DBC)44.8%20.9%1.67-6.7%
    Real Estate (VNQ)4.8%13.8%0.0910.7%
    Bitcoin (BTCUSD)-33.8%44.2%-0.8116.4%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with HIND
    HIND-31.7%88.3%-1.46-
    Sector ETF (XLV)7.7%15.2%0.3118.7%
    Equity (SPY)13.9%17.1%0.6214.6%
    Gold (GLD)18.5%18.9%0.793.1%
    Commodities (DBC)10.0%19.6%0.39-6.1%
    Real Estate (VNQ)1.3%18.8%-0.0411.6%
    Bitcoin (BTCUSD)11.2%52.0%0.3913.0%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with HIND
    HIND-17.3%88.3%-1.46-
    Sector ETF (XLV)11.0%16.7%0.5318.7%
    Equity (SPY)15.5%17.9%0.7314.6%
    Gold (GLD)11.8%16.4%0.593.1%
    Commodities (DBC)8.2%18.1%0.37-6.1%
    Real Estate (VNQ)4.5%20.7%0.1811.6%
    Bitcoin (BTCUSD)63.3%66.2%1.0313.0%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date9152026
    Short Interest: Shares Quantity0.0 Mil
    Short Interest: % Change Since 831202613.0%
    Average Daily Volume0.0 Mil
    Days-to-Cover Short Interest2.6 days
    Basic Shares Quantity7.0 Mil
    Short % of Basic Shares0.3%

    Earnings Returns History

    Updated 9/27/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/25/2026-3.1%-2.7%-7.6%
    5/29/2026-0.4%-2.1%-9.4%
    11/19/20253.5%11.5%-15.8%
    SUMMARY STATS   
    # Positive110
    # Negative223
    Median Positive3.5%11.5% 
    Median Negative-1.8%-2.4%-9.4%
    Max Positive3.5%11.5% 
    Max Negative-3.1%-2.7%-15.8%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/25/2026-3.1%-2.7%-7.6%
    5/29/2026-0.4%-2.1%-9.4%
    11/19/20253.5%11.5%-15.8%
    SUMMARY STATS   
    # Positive110
    # Negative223
    Median Positive3.5%11.5% 
    Median Negative-1.8%-2.4%-9.4%
    Max Positive3.5%11.5% 
    Max Negative-3.1%-2.7%-15.8%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/12/202610-Q
    03/31/202605/12/202610-Q
    12/31/202503/18/202610-K
    09/30/202511/14/202510-Q
    06/30/202410/01/2024S-4
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/12/202610-Q
    03/31/202605/12/202610-Q
    12/31/202503/18/202610-K
    09/30/202511/14/202510-Q
    06/30/202410/01/2024S-4

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 10/9/2026